ALGS (Aligos Therapeutics, Inc.) Earnings per share for the last twelve months

Public company logo of Aligos (ALGS)

Aligos Therapeutics (ALGS) competes in the field of clinical trials to combat metabolic pathologies and chronic hepatitis B. The business relies on the development of comprehensive therapies for the complete eradication of the virus, expanding patient reach. This chart of the current share price demonstrates the 48.70 metric, while the company's development depends on scientific discoveries and trial stages rather than market cycles.

Aligos Therapeutics, Inc. (ALGS): Earnings per share for the last twelve months from 02/11/2024 to 11/16/2026

ALGS (aligos.com): analytical breakdowns and indicator data

- market price and analyst price targets:
- business market valuation indicators:
Fundamental company valuation:ALGS (Aligos Therapeutics Inc.)
Mass-produced product of Aligos Therapeutics

This metric measures the annual dynamics of net income per share, reflecting the rate of change in capital efficiency by comparing the current twelve-month period with the previous equivalent. Analysis of the relative EPS YoY TTM chart for Aligos Therapeutics (ALGS) reveals the impact of staged investments in clinical trials for liver drugs, where the absence of revenue transforms the metric into an indicator of the cash burn rate.